Previous Close | 116.88 |
Open | 116.85 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 115.56 - 116.88 |
52 Week Range | 115.55 - 141.95 |
Volume | |
Avg. Volume | 308,604 |
Market Cap | 321.492B |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | 18.69 |
EPS (TTM) | 6.23 |
Earnings Date | N/A |
Forward Dividend & Yield | 3.04 (2.61%) |
Ex-Dividend Date | Apr 11, 2022 |
1y Target Est | 147.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for NSRGY
Biden said on Twitter the initial military cargo plane flights under "Operation Fly Formula" meant that "up to 1.5 million bottles of safe Nestlé infant formula will be coming to U.S. shelves as soon as possible." A Feb. 17 recall by top baby formula maker Abbott Laboratories during an investigation by the Food and Drug Administration has created one of the most urgent food shortages in recent history for U.S. families.
Top infant formula makers, including Reckitt Benckiser, Nestle and Danone SA, are also ramping up supplies to the country. Abbott recalls dozens of types of powdered baby formulas, including Similac, Alimentum and EleCare, made at its Sturgis, Michigan plant after four consumers complained about bacterial infections in infants who had consumed those products; Recalled products had an expiry date of April 1, 2022 or later. China's custom officials warn consumers against buying and consuming certain of Abbott's infant and baby products.
Europe's Nestlé SA (OTC: NSRGF) is ramping up hypoallergenic (HA) baby formula production to alleviate the shortage in U.S. supermarkets. In a statement sent to Fortune, Nestlé said it "significantly increased" Gerber Good Start Extensive HA production from the Netherlands and Alfamino from Switzerland, both used to treat babies that respond allergically to sugars like lactose. Nestlé declined to be more specific on the size of increased shipments. A recall by Abbott Laboratories (NYSE: ABT), pe